Breast cancer | Carboplatin-treated lung cancer | Cisplatin-treated lung cancer | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
All | Older 5-HT3RAs | Palonosetron | P | All | Older 5-HT3RAs | Palonosetron | P | All | Older 5-HT3RAs | Palonosetron | P | |
N | 3,606 | 1,742 | 1,864 | 4,497 | 2,691 | 1,806 | 1,154 | 764 | 390 | |||
Age mean (SD) | 53.7 (9.8) | 53.7 (9.7) | 53.7 (10.0) | NS | 64.9 (10.2) | 64.77 (10.2) | 65.03 (10.3) | NS | 60.5 (9.8) | 60.1 (9.8) | 61.3 (9.8) | 0.0476 |
CCI mean (SD) | 0.5 (1.0) | 0.5 (1.1) | 0.5 (1.0) | NS | 6.8 (3.2) | 6.87 (3.2) | 6.71 (3.2) | NS | 6.5 (3.3) | 6.6 (3.3) | 6.3 (3.2) | NS |
Female, N (%) | - | - | - | - | 2,080 (46.3) | 1,258 (46.8) | 822 (45.5) | NS | 459 (39.8) | 329 (43.1) | 130 (33.3) | 0.0014 |
Year of 5-HT 3 RA initiated | <0.0001 | <0.0001 | NS | |||||||||
2005 | 1,428 (39.6) | 753 (43.3) | 675 (36.2) | 1,562 (34.7) | 990 (36.8) | 572 (31.7) | 348 (30.2) | 247 (32.3) | 101 (25.9) | |||
2006 | 1,537 (42.6) | 720 (41.3) | 817 (43.8) | 1,480 (32.9) | 857 (31.9) | 623 (34.5) | 394 (34.1) | 263 (34.4) | 131 (33.6) | |||
2007 | 520 (14.4) | 223 (12.8) | 297 (15.9) | 1,140 (25.4) | 687 (25.5) | 453 (25.1) | 315 (27.3) | 194 (25.4) | 121 (31.0) | |||
2008 | 121 (3.4) | 46 (2.6) | 75 (4.0) | 315 (7.0) | 157 (5.8) | 158 (8.8) | 97 (8.4) | 60 (7.9) | 37 (9.5) |